FBLG vs. ATAI, NATR, ESPR, ANRO, ADCT, AMRN, RANI, ORGO, URGN, and PGEN
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Atai Life Sciences (ATAI), Nature's Sunshine Products (NATR), Esperion Therapeutics (ESPR), Alto Neuroscience (ANRO), ADC Therapeutics (ADCT), Amarin (AMRN), Rani Therapeutics (RANI), Organogenesis (ORGO), UroGen Pharma (URGN), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Atai Life Sciences (NASDAQ:ATAI) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking.
In the previous week, Atai Life Sciences had 2 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Atai Life Sciences and 2 mentions for FibroBiologics. Atai Life Sciences' average media sentiment score of 0.82 beat FibroBiologics' score of 0.47 indicating that FibroBiologics is being referred to more favorably in the news media.
FibroBiologics has lower revenue, but higher earnings than Atai Life Sciences.
28.4% of Atai Life Sciences shares are owned by institutional investors. 30.0% of Atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Atai Life Sciences received 325 more outperform votes than FibroBiologics when rated by MarketBeat users.
FibroBiologics has a net margin of 0.00% compared to FibroBiologics' net margin of -12,810.51%. Atai Life Sciences' return on equity of 0.00% beat FibroBiologics' return on equity.
Atai Life Sciences presently has a consensus price target of $10.50, indicating a potential upside of 444.04%. Given FibroBiologics' higher probable upside, research analysts plainly believe Atai Life Sciences is more favorable than FibroBiologics.
Summary
Atai Life Sciences beats FibroBiologics on 7 of the 12 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
